



Tel: 604.714.3600 Fax: 604.714.3669 Web: manningelliott.com

November 9, 2021

To: British Columbia Securities Commission

Alberta Securities Commission Ontario Securities Commission

Financial and Consumer Services Commission, New Brunswick

Financial and Consumer Affairs Authority of Saskatchewan, Securities Division

(collectively, the "Securities Commissions")

Re: ASEP Medical Inc. (the "Company")

We refer you to the Final Long Form Prospectus (the "Prospectus") of ASEP Medical Holdings Inc. (formerly Trenchant Life Sciences Investment Corp.) ("ASEP Holdings") dated November 9, 2021 to qualify the distribution of an aggregate of 11,731,500 common shares in the capital of ASEP Holdings (each, a "Common Share") issuable upon the deemed exercise of 11,731,500 issued and outstanding special warrants (each, a "Special Warrant") of ASEP Holdings.

We consent to being named in the Prospectus and to the use in the Prospectus of our report dated August 26, 2021 to the shareholders and directors of the Company on the following financial statements:

- Statement of financial position as at December 31, 2020; and
- Statements of comprehensive loss, changes in equity (deficiency) and cash flows for the period from incorporation on August 12, 2020 to December 31, 2020 and a summary of significant accounting policies and other explanatory information.

We report that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from these financial statements upon which we have reported or that are within our knowledge as a result of our audit of these financial statements. We have complied with the Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,

MANNING ELLIOTT LLP

Manning Elliott LLP